A carregar...
Are We Sure that Adjuvant Chemotherapy is the Best Approach for Resectable Pancreatic Cancer? Are We in the Era of Neoadjuvant Treatment? A Review of Current Literature
The outcome of pancreatic cancer is poor, with a 9% 5-year survival rate. Current treatment recommendations in the 10%−20% of patients who present with resectable disease support upfront resection followed by adjuvant therapy. Until now, only early complete surgical (R0) resection and adju...
Na minha lista:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI AG
2019-11-01
|
| Colecção: | Journal of Clinical Medicine |
| Assuntos: | |
| Acesso em linha: | https://www.mdpi.com/2077-0383/8/11/1922 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|